Evaluating the cost effectiveness of the addition 2011 RAFIA.pdf (107.38 kB)
0/0

Evaluating the cost-effectiveness of the addition of rituximab to chemotherapy in the first-line treatment of Follicular Lymphoma patients in the UK

Download (107.38 kB)
poster
posted on 25.02.2020 by Rachid Rafia, Diana Papaioannou, Matthew Stevenson, J. Rathbone, Helen Woods
INTRODUCTION Follicular lymphoma (FL), a clinical subtype of Non-Hodgkin’s lymphoma (NHL) , develops slowly and often without symptoms for many years. In 2008, the incidence of FL in England and Wales was 3.4 per 100,000 persons. Over 70% of FLs are diagnosed in persons aged over 60 years, and 85-90% present with advanced disease, which is defined as lymph nodes on both sides of the diaphragm being involved (stage III) or disease is disseminated with one or more extra-lymphatic organs involved (stage IV). Advanced FL is not curable, thus the aim of disease management is to both increase patient life expectancy and to increase patient health-related quality of life. The objective of this study is to assess, from a UK NHS perspective, the cost-effectiveness of the addition of rituximab (R) to selected chemotherapies: CVP (cyclophosphamide, vincristine and prednisolone); CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) and MCP (mitoxantrone, chlorambucil and prednisolone) in the first-line treatment of follicular lymphoma.

History

Ethics

There is no personal data or any that requires ethical approval

Policy

The data complies with the institution and funders' policies on access and sharing

Sharing and access restrictions

The data can be shared openly

Data description

  • The file formats are open or commonly used

Methodology, headings and units

  • Headings and units are explained in the files

Licence

Exports